Brind.
  1. Moderna and Merck personalized cancer vaccine advancement
  2. Moderna and Merck developed personalized mRNA cancer vaccine Intismeran following trial success, leading to a surge in Moderna's shares.

Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.

9 reports, 6 independent Updated Thu 00:00
No new developments lately
Reports
9
Developments
4
Repetition
56%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 6 independent outlets

Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.

Who's involved

What this event is mainly about
ModernaMerck

How it developed

Newest first. Tap a step to see who reported it.
  1. Analysts commented on Moderna and Merck stocks following the cancer vaccine partnership announcement.1 source
  2. Analyst firms like Citigroup and TD Cowen commented on the stock reaction following the Moderna-Merck vaccine partnership.1 source
  3. Analyst sentiment shifts regarding the Moderna/Merck mRNA cancer vaccine co-development, leading to market coverage and stock downgrades.1 source
  4. Goldman Sachs and UBS upgraded Moderna/Merck stock ratings following positive trial data.1 source

Keep exploring

Part of

Moderna and Merck developed personalized mRNA cancer vaccine Intismeran following trial success, leading to a surge in Moderna's shares. All 2 developments

Within Moderna and Merck personalized cancer vaccine advancement

The entities involved

Related events

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story